Chase Expands its Biotechnology Research Team
NEW YORK--(BUSINESS WIRE)--May 23, 2000--The Chase Manhattan Corporation
(NYSE: CMB - news) announced today that David T. Molowa, Ph. D. has
joined
Chase H&Q's equity research team, covering the biotechnology sector. Dr.
Molowa joins as a managing director. In addition to Dr. Molowa, the firm
also announced the addition of Maged Shenouda, Ronald Renaud and Alan
Meyers
to the firm's biotechnology research effort.
``These hires are a clear illustration of our commitment to this dynamic
sector,'' says Douglas Braunstein, head of the firm's healthcare banking
group and head of global mergers and acquisitions. ``We are extremely
pleased that David, Maged, Ronald and Alan have joined the Chase team.''
Dr.
Molowa will report to Todd Bakar, managing director and director of
equity
research. Mr. Shenouda, Mr. Renaud and Mr. Meyers will report to Mr.
Molowa.
``Chase already has a top-notch research team in this sector with Rob
Olan
and Meg Malloy leading that effort,'' continued Todd Bakar. ``With our
expanded team, we will be able to increase the breadth and depth of our
research ability.''
Dr. Molowa joins Chase from Bear, Stearns & Company where he was senior
managing director and responsible for the coverage of the life sciences
technology companies. He has been selected for Institutional Investor's
All-American Research team for the past seven years. Dr. Molowa holds a
Ph.
D. from the Medical College of Virginia, a M.B.A. from Rutgers
University
and a B.S. from the University of Richmond. Previous to joining Bear,
Stearns, he was a senior research biochemist at Merck & Co.
Mr. Shenouda joins Chase from Bear, Stearns & Company where he was a
vice
president in equity research covering the biotechnology and European
pharmaceuticals industries for large cap companies. Mr. Shenouda holds a
M.B.A. from Rutgers and a B.S. from St. John's University. Mr. Renaud
and
Mr. Meyers were previously at Bear, Stearns & Company in the
biotechnology
group in equity research. |
